Clinical Trials Arena October 2, 2025
Two experts discussed innovative trial designs in rare disease research, common challenges and the potential of AI to enhance research.
“The biggest shifts in rare disease clinical research are occurring in platform and basket trials, which from the perspective of small and mid-sized biotechs, remain highly complicated in terms design and in statistical requirements”, says George Tetz, CEO New York-based biotech Second Life Therapeutics.
Tetz made these remarks at Arena International’s 3rd Annual Clinical Trials in Rare Diseases (CTRD) meeting, during a panel discussing the future of rare disease clinical trials along with Bruce Bloom, CEO of the rare disease biotech Fortuity Pharma. The meeting took place on 17-18 September in Princeton, New Jersey, US.
Platform trials offer flexibility and...
Today's Sponsors
Today's Sponsor